162 related articles for article (PubMed ID: 35510091)
1. Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with
Amin A; Nelson WW; Dreyfus J; Wong AC; Mohammadi I; Teigland C; Dahdal DN; Feuerstadt P
Ther Adv Infect Dis; 2022; 9():20499361221095679. PubMed ID: 35510091
[TBL] [Abstract][Full Text] [Related]
2. Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults.
Feuerstadt P; Nelson WW; Drozd EM; Dreyfus J; Dahdal DN; Wong AC; Mohammadi I; Teigland C; Amin A
J Am Med Dir Assoc; 2022 Oct; 23(10):1721-1728.e19. PubMed ID: 35288083
[TBL] [Abstract][Full Text] [Related]
3. Health care resource utilization and costs of recurrent
Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
[No Abstract] [Full Text] [Related]
4. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
5. Clinical burden of recurrent
Feuerstadt P; Nelson WW; Teigland C; Dahdal DN
Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e60. PubMed ID: 36483433
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.
Bouza E; Cobo J; Rodríguez-Hernández MJ; Salavert M; Horcajada JP; Iribarren JA; Obi E; Lozano V; Maratia S; Cuesta M; Uría E; Limón E
Rev Esp Quimioter; 2021 Apr; 34(2):126-135. PubMed ID: 33618513
[TBL] [Abstract][Full Text] [Related]
7. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.
Reveles KR; Yang M; Garcia-Horton V; Edwards ML; Guo A; Lodise T; Bochan M; Tillotson G; Dubberke ER
Adv Ther; 2023 Jul; 40(7):3104-3134. PubMed ID: 37210680
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.
Tricotel A; Antunes A; Wilk A; Dombrowski S; Rinta-Kokko H; Andersson FL; Ghosh S
BMC Infect Dis; 2024 Mar; 24(1):357. PubMed ID: 38539166
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of real-world healthcare resource use and costs of
Malone DC; Armstrong EP; Gratie D; Pham SV; Amin A
Antimicrob Steward Healthc Epidemiol; 2023; 3(1):e17. PubMed ID: 36714290
[TBL] [Abstract][Full Text] [Related]
10. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.
Zhang D; Prabhu VS; Marcella SW
Clin Infect Dis; 2018 Apr; 66(9):1326-1332. PubMed ID: 29360950
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
[TBL] [Abstract][Full Text] [Related]
12. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
Kunishima H; Ito K; Laurent T; Abe M
J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
[TBL] [Abstract][Full Text] [Related]
13. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
14. Clinical complications in patients with primary and recurrent
Feuerstadt P; Boules M; Stong L; Dahdal DN; Sacks NC; Lang K; Nelson WW
SAGE Open Med; 2021; 9():2050312120986733. PubMed ID: 33505698
[TBL] [Abstract][Full Text] [Related]
15. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
Kimura T; Snijder R; Sugitani T
J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
[TBL] [Abstract][Full Text] [Related]
16. Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study.
Kuntz JL; Baker JM; Kipnis P; Li SX; Liu V; Xie Y; Marcella S; Escobar GJ
Infect Control Hosp Epidemiol; 2017 Jan; 38(1):45-52. PubMed ID: 27760583
[TBL] [Abstract][Full Text] [Related]
17. An Observational Cohort Study of
Rao K; Higgins PDR; Young VB
mSphere; 2018; 3(3):. PubMed ID: 29794054
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes.
Tresman R; Goldenberg SD
J Antimicrob Chemother; 2018 Oct; 73(10):2851-2855. PubMed ID: 29982502
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study.
Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
BMC Infect Dis; 2014 Jun; 14():306. PubMed ID: 24898123
[TBL] [Abstract][Full Text] [Related]
20. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.
Wilcox MH; Ahir H; Coia JE; Dodgson A; Hopkins S; Llewelyn MJ; Settle C; Mclain-Smith S; Marcella SW
J Antimicrob Chemother; 2017 Sep; 72(9):2647-2656. PubMed ID: 28633368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
